Lowest Price Guaranteed From USD 4,899
The automated cell processing system market is estimated to be worth $220 million in 2020 and is expected to grow at CAGR of 16% during the forecast period. Advanced therapy medicinal products (ATMPs), such as cell therapies and gene therapies, have revolutionized the healthcare sector. Over the past two decades, more than 30 ATMPs have been approved. Moreover, according to a recent report (published by The Alliance for Regenerative Medicine), over 1,050 clinical trials are currently being conducted by over 1,000 companies, worldwide, focused on the evaluation of cell and gene therapies. However, despite the numerous advances in automated cell processing system market, there are certain challenges that need to be addressed in order to achieve commercial success. For instance, the current cell therapy manufacturing process is labor-intensive, time consuming and costly. Further, the production of most of these specialized therapeutic products requires manual labor and are typically carried out discretely (open processing), thereby, rendering the processes difficult to scale-up, with high risk of contamination. Another concern faced by cell and gene therapy manufacturers is batch-to-batch variability, given that even a minor change in the production protocol can affect the quality of the resulting product. Consequently, cell therapies are exorbitantly priced, ranging from USD 300,000 to USD 500,000 per dose.
Experts believe that some of the existing challenges related to cell therapy manufacturing can be addressed through the adoption of automated and closed cell processing systems. These solutions have been demonstrated to be capable of enabling stakeholders to manage various aspects of the cell therapy manufacturing process efficiently, while complying to global regulatory standards. Other benefits of such systems include reduced risk of contamination, optimum utilization of facility and resources, limited in-process variation and consistent product quality. Further, the use of such automated systems enable significant reductions (in the range of 40% to 90%) in labor costs. In recent years, the cost saving potential of these systems, coupled to their ability to streamline and simplify the complex cell therapy processing (from initial cell collection till final formulation), has effectively captured the interest of several stakeholders engaged in automated cell processing system market. Given the growing demand for cost-effective, personalized medicine, coupled to the benefits of automated and closed systems, we believe that this niche market is poised to witness significant market growth in the foreseen future.
Several recent developments have taken place in the field of automated cell processing system market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
Examples of key companies engaged in automated cell processing system market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Cytiva, Pall, Terumo BCT and ThermoGenesis. This market report includes an easily searchable excel database of all the companies providing automated cell processing system for apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing of cell therapy, worldwide.
The “Automated Cell Processing System Market: Focus on Apheresis, Expansion, Harvest, Fill / Finish, Cryopreservation, Thawing, 2020-2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the automated cell processing system market. The market research report also features a detailed analysis of key drivers and trends related to automated cell processing system market. Amongst other elements, the market research report includes:
The key objective of automated cell processing system market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for automated cell processing system market during the forecast period. Based on various parameters, such as number of cell therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different automated and closed cell processing systems, we have developed informed estimates of the evolution of the market, over the forecast period 2020-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different cell therapy processing steps (apheresis, separation, expansion, harvest, fill / finish, cryopreservation and thawing), [B] scale of operations (pre-clinical / clinical and commercial organizations), [C] end users (hospitals / medical centers / clinics, research institutes / academic institutes, laboratories, commercial organizations), and [D] key geographical regions (North America, Europe, Asia-Pacific, Middle East and Latin America). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.
The opinions and insights presented in the market report were influenced by discussions held with senior stakeholders in the industry. The market research report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.